Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lifecore Biomedical (LFCR) Other Non-Current Liabilities: 2010-2025

Historic Other Non-Current Liabilities for Lifecore Biomedical (LFCR) over the last 10 years, with May 2025 value amounting to $25.0 million.

  • Lifecore Biomedical's Other Non-Current Liabilities fell 1.61% to $25.0 million in Q2 2025 from the same period last year, while for May 2025 it was $25.0 million, marking a year-over-year decrease of 1.61%. This contributed to the annual value of $25.0 million for FY2025, which is 1.61% down from last year.
  • As of Q2 2025, Lifecore Biomedical's Other Non-Current Liabilities stood at $25.0 million, which was up 4.56% from $23.9 million recorded in Q1 2025.
  • Lifecore Biomedical's 5-year Other Non-Current Liabilities high stood at $64.9 million for Q2 2023, and its period low was $190,000 during Q2 2022.
  • Moreover, its 3-year median value for Other Non-Current Liabilities was $24.7 million (2024), whereas its average is $31.9 million.
  • In the last 5 years, Lifecore Biomedical's Other Non-Current Liabilities crashed by 93.38% in 2022 and then surged by 34,057.89% in 2023.
  • Lifecore Biomedical's Other Non-Current Liabilities (Quarterly) stood at $1.9 million in 2021, then slumped by 89.60% to $201,000 in 2022, then skyrocketed by 21,790.55% to $44.0 million in 2023, then tumbled by 47.05% to $23.3 million in 2024, then dropped by 1.61% to $25.0 million in 2025.
  • Its last three reported values are $25.0 million in Q2 2025, $23.9 million for Q1 2025, and $23.3 million during Q4 2024.